Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod AlphaGlobeNewsWire • 09/14/22
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue SarcomaGlobeNewsWire • 09/06/22
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway InhibitorGlobeNewsWire • 08/30/22
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLCGlobeNewsWire • 08/01/22
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3GlobeNewsWire • 07/06/22
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung CancerGlobeNewsWire • 06/27/22
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-ComersGlobeNewsWire • 06/03/22
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022GlobeNewsWire • 05/27/22
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual MeetingGlobeNewsWire • 04/28/22
Immutep's Efti in Combination with MSD's Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer PatientsGlobeNewsWire • 03/30/22
Immutep Announces Publication of TACTI-002 Abstract at ESMO's European Lung Cancer Congress 2022GlobeNewsWire • 03/24/22
Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure PlaySeeking Alpha • 03/21/22
Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO's Breast Cancer Congress 2022GlobeNewsWire • 03/18/22
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525GlobeNewsWire • 03/18/22
Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast CancerGlobeNewsWire • 03/10/22
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO's European Lung Cancer Congress 2022GlobeNewsWire • 02/18/22
Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway InhibitorGlobeNewsWire • 02/11/22